Aprea Therapeutics Reports Second Unconfirmed Partial Response for WEE1 Inhibitor APR-1051 in Phase 1 Study
APRE sits 28% above its 52-week low of $0.548 on light trading volume (0.1× avg).
Summary
Aprea Therapeutics reported a second unconfirmed partial response for its WEE1 inhibitor, APR-1051, in a Phase 1 study, showing significant tumor shrinkage and biomarker reduction with good tolerability.
Key Events · Product Development and Regulatory · APRE
-
Second Unconfirmed Partial Response Achieved
A patient with advanced endometrial cancer in the Phase 1 ACESOT-1051 study achieved a second unconfirmed partial response (uPR) at the 220 mg dose level.
-
Significant Tumor Shrinkage and Biomarker Reduction
The responding patient showed a 50% reduction in target lesion measurements and an 87% decline in the CA-125 tumor biomarker, from 362 U/mL to 47 U/mL.
-
Favorable Safety Profile
The patient experienced only Grade 1 treatment-emergent adverse events and continues treatment, supporting a potentially improved therapeutic index for APR-1051.
-
Genomically Guided Patient Selection
Both patients with uPRs to date harbored PPP2R1A mutations, reinforcing the mechanistic thesis of targeting WEE1 for this specific patient population.
Analysis · APRE · Life Sciences
Aprea Therapeutics announced a second unconfirmed partial response (uPR) in its Phase 1 ACESOT-1051 study for its WEE1 inhibitor, APR-1051. This positive clinical update is highly significant for the micro-cap biopharmaceutical company, especially following a recent Nasdaq deficiency letter and a dilutive private placement. The observed 50% tumor shrinkage and substantial 87% reduction in the CA-125 biomarker, coupled with a favorable safety profile (only Grade 1 adverse events), provide further evidence of APR-1051's biological activity and therapeutic potential in advanced endometrial cancer patients with PPP2R1A mutations. This reinforces the company's development strategy and could help improve investor sentiment and address concerns about its financial and compliance status. Investors should monitor the confirmation of these responses and the further update expected in Q2 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APRE was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.55 to $3.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.